Mendus AB (publ) (STO:IMMU)
Sweden · Delayed Price · Currency is SEK 5.69
+0.01 (0.18%)
May 22, 2026, 5:29 PM CET
Mendus AB Company Description
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers.
The company’s lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2.
It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel.
The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022.
Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Mendus AB (publ)
| Country | Sweden |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Erik Manting |
Contact Details
Address: Västra Trädgårdsgatan 15 Stockholm, 111 53 Sweden | |
| Phone | 46 87 32 84 00 |
| Website | mendus.com |
Stock Details
| Ticker Symbol | IMMU |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0005003654 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Erik Manting Ph.D. | Chief Executive Officer |
| Lotta Ferm | Chief Financial Officer |
| Dr. Tariq Mughal M.D. | Chief Medical and Scientific Officer |